Carnitine Palmitoyltransferase (CPT) Inhibitor

Carnitine Palmitoyltransferase (CPT) Inhibitors (30):

Cat. No.	Product Name	Effect	Purity

HY-50202

Etomoxir	Inhibitor	99.58%
Etomoxir ((R)-(+)-Etomoxir) is an irreversible inhibitor of carnitine palmitoyltransferase 1a (CPT-1a), inhibits fatty acid oxidation (FAO) through CPT-1a and inhibits palmitate β-oxidation in human, rat and guinea pig.

HY-50202A

Etomoxir sodium salt	Inhibitor	99.62%
Etomoxir((R)-(+)-Etomoxir) sodium salt is an irreversible inhibitor of carnitine palmitoyltransferase 1a (CPT-1a), inhibits fatty acid oxidation (FAO) through CPT-1a and inhibits palmitate β-oxidation in human, rat and guinea pig.

HY-B1334A

Perhexiline maleate	Inhibitor	99.97%
Perhexiline maleate is an orally active CPT1 and CPT2 inhibitor that reduces fatty acid metabolism. Perhexiline maleate induces mitochondrial dysfunction and apoptosis in hepatic cells. Perhexiline maleate can cross the blood brain barrier (BBB) and shows anti-tumor activity. Perhexiline maleate can be used in the research of cancers, and cardiovascular disease like angina.

HY-W012865

Tartronic acid	Inhibitor	≥98.0%
Tartronic acid, a dicarboxylic acid derive, is an inhibitor of the transformation of carbohydrates into fat under fat-deficient diet conditions. Tartronic acid promotes 3T3-L1 adipocyte differentiation by increasing the protein expression of FABP-4, PPARγ and SREBP-1. Tartronic acid promotes de novo lipogenesis and inhibits CPT-1β by upregulating acetyl-CoA and malonyl-CoA. Tartronic acid promotes weight gain and induces adipocyte hypertrophy in epididymal white adipose tissue and lipid accumulation in the livers of high-fat diet induced obese mice. Tartronic acid can be used for lipid metabolic disease research.

HY-182248

Teglicar chloride	Inhibitor
Teglicar chloride (ST1326 chloride) is an orally active, reversible, mixed-type, selective inhibitor of hepatic carnitine palmitoyltransferase I (L-CPT I), with an IC₅₀ of 1.1 μM against rat L-CPT I. Teglicar chloride reduces serum glucose levels. Teglicar chloride exhibits antiketotic activity in normal fasted rats. Teglicar chloride can be used in research related to type 2 diabetes and ketoacidosis.

HY-136408

Malonyl CoA lithium	Inhibitor	99%
Malonyl CoA (Malonyl Coenzyme A) lithium is an inhibitor of carnitine palmitoyl transferase 1 (CPT1). High Malonyl CoA lithium concentrations suppress fatty acid oxidation, while low Malonyl CoA lithium concentrations are permissive for fat oxidation.

HY-16482

Teglicar	Inhibitor	98.0%
Teglicar is a selective and reversible orally active liver isoform of carnitine palmitoyl-transferase 1 (L-CPT1) inhibitor with an IC₅₀ value of 0.68 μM and a K_i value of 0.36 μM. Teglicar has a potential antihyperglycemic propert. Teglicar can be used for the research of diabetes and neurodegenerative disease including Huntington's disease (HD).

HY-B1334

Perhexiline	Inhibitor	99.96%
Perhexiline is an orally active CPT1 and CPT2 inhibitor that reduces fatty acid metabolism. Perhexiline induces mitochondrial dysfunction and apoptosis in hepatic cells. Perhexiline can cross the blood brain barrier (BBB) and shows anti-tumor activity. Perhexiline can be used in the research of cancers, and cardiovascular disease like angina.

HY-RS03122

CPT1A Human Pre-designed siRNA Set A	Inhibitor
CPT1A Human Pre-designed siRNA Set A contains three designed siRNAs for CPT1A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-W104819

4-Hydroxyphenylglyoxylate	Inhibitor	99.30%
4-Hydroxyphenylglyoxylate (4-Hydroxyphenylglyoxylic acid) is an inhibitor of carnitine palmitoyltransferase I (CPT I). 4-Hydroxyphenylglyoxylate can be used to study sensitivity changes in CPT I of liver mitochondria and fatty acid oxidation by isolated hepatocytes. 4-Hydroxyphenylglyoxylate can inhibits fatty acid oxidation.

HY-W420033

(S)-(+)-Etomoxir	Inhibitor	98.65%
(S)-(+)-Etomoxir is the S enantiomer of Etomoxir (HY-50202). Etomoxir is an irreversible inhibitor of carnitine palmitoyltransferase 1a (CPT-1a), inhibits fatty acid oxidation (FAO) through CPT-1a and inhibits palmitate β-oxidation in human, rat and guinea pig.

HY-U00159

McN3716	Inhibitor	99.66%
McN3716 is a carnitine palmitoyltransferase I (CPT-1) inhibitor.

HY-161027

2,6-Didehydropeperomin B	Inhibitor
DHP-B is an Ecolignan-type compound and covalent, selective CPT1A inhibitor with a K_d of 1.62 μM. DHP-B can be isolated from the plant Peperomia dindygulensis. DHP-B covalently binds to Cys96 of CPT1A, blocks FAO, and disrupts the mitochondrial CPT1A-VDAC1 interaction. DHP-B triggers Apoptosis. DHP-B exhibits anti-CRC activity.

HY-50202R

Etomoxir (Standard)	Inhibitor
Etomoxir (Standard) is the analytical standard of Etomoxir. This product is intended for research and analytical applications. Etomoxir ((R)-(+)-Etomoxir) is an irreversible inhibitor of carnitine palmitoyltransferase 1a (CPT-1a), inhibits fatty acid oxidation (FAO) through CPT-1a and inhibits palmitate β-oxidation in human, rat and guinea pig.

HY-RS23907

Cpt2 Rat Pre-designed siRNA Set A	Inhibitor
Cpt2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cpt2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS16248

Cpt1a Mouse Pre-designed siRNA Set A	Inhibitor
Cpt1a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cpt1a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS03125

CPT2 Human Pre-designed siRNA Set A	Inhibitor
CPT2 Human Pre-designed siRNA Set A contains three designed siRNAs for CPT2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-16149

SDZ-CPI 975	Inhibitor
SDZ-CPI-975 is a novel, reversible, and selective CPT I inhibitor. SDZ-CPI-975 effectively inhibits fatty acid oxidation and lowers blood glucose levels.

HY-RS03123

CPT1B Human Pre-designed siRNA Set A	Inhibitor
CPT1B Human Pre-designed siRNA Set A contains three designed siRNAs for CPT1B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS03124

CPT1C Human Pre-designed siRNA Set A	Inhibitor
CPT1C Human Pre-designed siRNA Set A contains three designed siRNAs for CPT1C gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Name
Email *

	Sorry, but the email address you supplied was invalid.